Pherecydes Pharma Overview

  • Founded
  • 2006

Founded
  • Status
  • Public

  • Employees
  • 27

Employees
  • Stock Symbol
  • ALPHE

Stock Symbol
  • Share Price
  • $2.45

  • (As of Monday Closing)

Pherecydes Pharma General Information

Description

Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on various bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Primary Office
  • 22 Boulevard Bénoni Goullin
  • 44200 Nantes
  • France
+33 01 00 00 00 00

Pherecydes Pharma Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pherecydes Pharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.45 $2.44 $1.92 - $7.86 $17.6M 7.19M 3.51K -$0.54

Pherecydes Pharma Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 22,309 39,313
Revenue 2,413 2,533 2,060 2,531
EBITDA (5,043) (4,921) (3,692) (2,747)
Net Income (3,145) (3,770) (1,591) (1,368)
Total Assets 14,213 15,947 9,688 7,837
Total Debt 2,494 2,744 492 1,342
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pherecydes Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pherecydes Pharma‘s full profile, request access.

Request a free trial

Pherecydes Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pherecydes Pharma‘s full profile, request access.

Request a free trial

Pherecydes Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on va
Drug Discovery
Nantes, France
27 As of 2022
000.00
00.00 0000-00-00
000000000 000.00

00000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000 000000000
Ness Ziona, Israel
000 As of 0000
00000
000000000 00000

000000

etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Cambridge, MA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pherecydes Pharma Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BiomX Formerly VC-backed Ness Ziona, Israel 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
0000 00000000000 Venture Capital-Backed Somerville, MA 0 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed Marina del Rey, CA 00 00000 000000000 00000
00000 00000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
You’re viewing 5 of 18 competitors. Get the full list »

Pherecydes Pharma Patents

Pherecydes Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3054874-A1 Phage therapy Pending 08-Mar-2017 000000000
EP-3372085-A1 Phage therapy Inactive 08-Mar-2017 000000000
EP-3592150-A1 Phage therapy Pending 08-Mar-2017 000000000
JP-2020510024-A Phage therapy Pending 08-Mar-2017 000000000 0
US-20200030392-A1 Phage therapy Pending 08-Mar-2017 A61K35/76
To view Pherecydes Pharma’s complete patent history, request access »

Pherecydes Pharma Executive Team (8)

Name Title Board Seat Contact Info
Didier Hoch Chief Executive Officer & Chairman
Thibaut Fayet Chief Executive Officer
Cindy Fevre Ph.D Chief Scientific Officer
You’re viewing 3 of 8 executive team members. Get the full list »

Pherecydes Pharma Board Members (11)

Name Representing Role Since
Claire Poulard Omnes Capital Supervisory Board Member 000 0000
Didier Hoch Pherecydes Pharma Chief Executive Officer & Chairman 000 0000
Eric Leire MD Self Supervisory Board Member 000 0000
Franck Lescure Ph.D Auriga Partners (Paris) Supervisory Board Member 000 0000
Guy Rigaud Self Supervisory Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Pherecydes Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial